Leerink analyst David Risinger views Spyre Therapeutics’ (SYRE) positive topline results from the open-label SPY001 monotherapy cohort in the Phase 2 SKYLINE platform trial in ulcerative colitis as incrementally positive for Oruka Therapeutics (ORKA), as it further validates the underlying antibody platform. Leerink remains bullish on Oruka shares ahead of topline results for the company’s ORKA-001 Phase 2a EVERLAST-A trial in Q2 2026. The firm reiterates an Outperform rating on Oruka.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ORKA:
- Oruka Therapeutics price target raised to $78 from $73 at BTIG
- Oruka Therapeutics price target raised to $70 from $40 at H.C. Wainwright
- Oruka Therapeutics price target raised to $78 from $50 at Barclays
- Oruka Therapeutics price target raised to $75 from $50 at UBS
- Oruka Therapeutics price target raised to $125 from $60 at Guggenheim